Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Clinical trials

Medical news
Regional

Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study

March 15, 2026March 13, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) reported additional data from its Phase 2 SKNJCT-003 clinical study evaluating the SkinJect microneedle delivery system for the treatment of basal cell …

Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study Read More

Johnson & Johnson
Regional

FDA Approves TECVAYLI and DARZALEX FASPRO Combo for Multiple Myeloma

March 13, 2026March 12, 2026 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults …

FDA Approves TECVAYLI and DARZALEX FASPRO Combo for Multiple Myeloma Read More
INOVIO Pharmaceuticals
Regional

INOVIO and Akeso Partner to Study New Glioblastoma Therapy

March 12, 2026March 11, 2026 - by Timothy Alexander

PLYMOUTH MEETING, PA — INOVIO and Akeso, Inc. announced a clinical trial collaboration to evaluate a combination immunotherapy as a potential treatment for Glioblastoma, the most common and aggressive form …

INOVIO and Akeso Partner to Study New Glioblastoma Therapy Read More

Medical
Regional

Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy

March 10, 2026March 9, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array treatment for basal cell carcinoma of the skin.

Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy Read More
Passage Bio
Regional

Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results

March 10, 2026March 9, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported fourth-quarter and full-year 2025 financial results while providing updates on its clinical program studying PBFT02, a gene therapy candidate for genetic …

Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results Read More

Ocugen
Research

Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy

March 10, 2026March 9, 2026 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group …

Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy Read More
Mural Health
Business

Mural Health Expands Clinical Trial Participant Payment Capabilities

March 9, 2026March 8, 2026 - by Timothy Alexander

BERWYN, PA — Mural Health announced it has expanded global payment capabilities within its Mural Link participant management platform to enable local payments to clinical trial participants in multiple countries.

Mural Health Expands Clinical Trial Participant Payment Capabilities Read More

Suvoda
Regional

Suvoda Adds Split Budget Feature to Clinical Trial Budgeting Software

March 8, 2026March 8, 2026 - by Timothy Alexander

CONSHOHOCKEN, PA — Suvoda announced the addition of split budget functionality to its Budgeting & Benchmarking software, a tool used by sponsors and contract research organizations to develop and manage …

Suvoda Adds Split Budget Feature to Clinical Trial Budgeting Software Read More
Medical research
Regional

Medicus Pharma Reports Phase 2 Results for Skin Cancer Patch

March 6, 2026March 6, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating a dissolvable microneedle patch designed to deliver chemotherapy directly into basal cell …

Medicus Pharma Reports Phase 2 Results for Skin Cancer Patch Read More
Aclaris Therapeutics
Research

Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma

March 4, 2026March 3, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) said it has initiated a randomized, placebo-controlled Phase 1b proof-of-concept trial of its investigational antibody ATI-052 in patients with asthma, as it …

Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma Read More

Posts pagination

Previous 1 … 4 5 6 … 37 Next

Trending News

  • CDC Warns Parents After Salmonella Cases Linked to Chameleons

  • Yellow Springs: Where Pennsylvania Kept Reinventing Itself

  • Expect Frustrating Delays on Phoenixville Pike This Week

  • Giant Barbecue Battle Returns to Washington in June

  • Luminiscence Opens Philadelphia Run at Cathedral Basilica

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

PHL gamma-butyrolactone

CBP Seizes Liquid Ecstasy Precursor Shipped to Massachusetts

May 9, 2026May 9, 2026

Court News

York Man Sentenced to Life in 2021 Park Shooting

May 9, 2026May 9, 2026

Justin L Pavetto

Special Needs Teacher Accused in Disturbing Child Predator Case

May 9, 2026May 9, 2026

Copyright © 2026 MyChesCo.